 Three years after receiving gene therapy from Orchard Therapeutics NASDAQ: ORTX in an early-stage clinical trial, 100 of patients with an inherited disease that damages the immune system were still alive. Data from a study that used Orchards gene therapy OTL-101 to treat adenosine deaminase severe combined immunodeficiency ADA-SCID were published in the New England Journal of Medicine. 